NCT03663829View on ClinicalTrials.gov

Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia

CompletedOBSERVATIONAL
Enrollment

2,052

Participants

Timeline

Start Date

October 4, 2017

Primary Completion Date

March 5, 2019

Study Completion Date

December 18, 2019

Conditions
Rheumatoid Arthritis
Interventions
OTHER

Non-Interventional

Non-Interventional

OTHER

Non-Interventional

Non-Interventional

Trial Locations (1)

Unknown

Canberra City

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03663829 - Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia | Biotech Hunter | Biotech Hunter